In this review:
Australian MM projections to 2040
Causes of death in MM patients in Australia
SLiM biomarker inclusion in diagnostic criteria for MM
Cevostamab for relapsed/refractory MM
Talquetamab in relapsed/refractory MM
ICANS with tisagenlecleucel for B cell ALL
ICANS with tisagenlecleucel for diffuse large B cell lymphoma
Ciltacabtagene autoleucel CAR T-cell therapy in RRMM
Immune tumour microenvironment in newly diagnosed MM
Whole genome sequencing identifies drivers of extramedullary progression
Please login below to download this issue (PDF)